MarketPulse

regulatory filing

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCryst Lands $70M European Deal for Hereditary Angioedema Drug

BioCryst secures $70M upfront plus $275M milestone payments for navenibart European rights, reinforcing strategy to focus on U.S. commercialization.
BCRXPhase 3 clinical trialORLADEYO
GlobeNewswire Inc.GlobeNewswire Inc.··Na

FEMSA Files 2025 Annual Report, Solidifying Position as Latin America's Retail Giant

FEMSA files 2025 annual report, reinforcing its position as a diversified Latin American retail and beverage conglomerate with 392,000+ employees across 18 countries.
KOFfinancial resultsannual report
BenzingaBenzinga··Surbhi Jain

Alphabet's $122B SpaceX Stake Emerges in Alaska Filing, Signals Major Asset Value

Alphabet disclosed 6.11% SpaceX stake valued at $122 billion in routine Alaska filing, originating from 2015 joint investment with Fidelity.
GOOGGOOGLventure capitalSpaceX IPO
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files Annual Reports With €230.9M Cash Pile Amid MASH Drug Development

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva Advances Biosimilar Pipeline With FDA Approval of PONLIMSI and Xolair Candidate

Teva gains FDA approval for PONLIMSI denosumab biosimilar and dual regulatory acceptance for omalizumab candidate, advancing biosimilar growth strategy.
AMGNNVSTEVAFDA approvalpharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Teva Pharmaceutical Industries Ltd.

Teva Scales Biosimilars Pipeline with FDA Approval of PONLIMSI, Xolair Candidate Filing

Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.
AMGNNVSTEVAFDA approvalbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva Gains Biosimilar Momentum With FDA Approval, Dual Regulatory Filings

Teva wins FDA approval for PONLIMSI biosimilar and dual regulatory filing acceptance for omalizumab biosimilar, advancing its 'Pivot to Growth' strategy.
AMGNNVSTEVAFDA approvalregulatory filing
GlobeNewswire Inc.GlobeNewswire Inc.··Unknown

Smarkets Eyes U.S. Expansion With CFTC License Bid Backed by Susquehanna

UK prediction market platform Smarkets, backed by trading firm Susquehanna, files for CFTC license to enter U.S. market using transparent pricing model.
SQCFprediction marketsregulatory filing
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi Files 2025 Annual Financial Reports with French and US Regulators

Sanofi filed its 2025 annual financial reports with French and U.S. regulators, including governance disclosures and buyback programs, maintaining dual-listing compliance.
SNYfinancial reportingsustainability